Skip to content
Screener

Amylyx Pharmaceuticals, Inc. AMLX Q1 2025 earnings

Reported May 8, 2025 · Before market open

Revenue-
EPS-$0.42Beat by $0.03
EPS estimate-$0.45

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$59.4K
EPS estimate-$0.38

Financials

Q1 2025

Income statement

See full
Revenue--100%
Gross profit--100%
Operating income-$37.8M+69.0%
Net income-$35.9M+69.8%
EPS (diluted)-$0.42+76.0%

Balance sheet

See full
Cash & equivalents$59.8M-65.0%
Total debt$1.4M-62.6%
Total equity$201.4M-37.9%
Total assets$219.7M-47.4%

Cash flow

See full
Operating cash flow-$39.8M-8,044%
CapEx$11.0K-83.6%
Free cash flow-$39.8M-7,065%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$313.65M+63.8%
Enterprise value$255.27M+938%

Profitability

See full
Gross margin101.3%+7.9pp
Operating margin37,957.8%+37,937pp
Net margin36,055.5%+36,038pp
FCF margin34,115.8%+34,112pp

Returns & leverage

See full
Return on equity-83.2%-126pp
Debt / equity0×0.0×
Current ratio12.1×+7.6×

FAQ

When did Amylyx Pharmaceuticals, Inc. report Q1 2025 earnings?
Amylyx Pharmaceuticals, Inc. (AMLX) reported Q1 2025 earnings on May 8, 2025 before market open.
What were Amylyx Pharmaceuticals, Inc.'s Q1 2025 revenue and EPS?
Amylyx Pharmaceuticals, Inc. reported revenue of - and eps of $-0.42 for Q1 2025.
Did Amylyx Pharmaceuticals, Inc. beat estimates in Q1 2025?
EPS beat the consensus estimate of $-0.45 by $0.03.
How did Amylyx Pharmaceuticals, Inc.'s Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 100.0% from $88.6M a year earlier and eps grew 8.7% from $-0.46.
Where can I find Amylyx Pharmaceuticals, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0000950170-25-066355) and the 10-Q periodic report (0000950170-25-066363) directly on SEC EDGAR. The filing index links above go to sec.gov.